Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: outer membrane protein targeting antibiotics - Basilea Pharmaceutica

Next Previous
Drug Profile

Research programme: outer membrane protein targeting antibiotics - Basilea Pharmaceutica

Alternative Names: OMPTA - Spexis; OMPTA BamA program - Spexis; Outer membrane protein targeting antibiotics - Spexis; PEM - Spexis; POL 7001; POL-0067; POL-6137; Protein epitope mimetic molecules - Spexis

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Polyphor; University of Zurich
  • Developer Basilea Pharmaceutica
  • Class Antibacterials; Cyclic peptides; Epitopes; Macrocyclic compounds; Peptidomimetics
  • Mechanism of Action Bacterial outer membrane protein modulators; Imp protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Gram-negative infections

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for preclinical development in Gram-negative-infections in Switzerland (SC)
  • 15 Jan 2024 Basilea Pharmaceutica acquires antibacterials research programme from Spexis
  • 07 Jun 2023 Antibacterial research programme is still in preclinical phase for Gram negative infections in Switzerlands

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top